Literature DB >> 1929512

Lipoprotein (a) concentrations as risk indicators for atherosclerosis.

G M Kostner1, A Czinner, K H Pfeiffer, M Bihari-Varga.   

Abstract

The plasma concentration of different lipoproteins were measured in 102 control children, in 42 children with a parent suffering from coronary heart disease (CHD), and in 50 children with a parent with cerebrovascular disease (CVD). Significant differences between controls and children in the other two groups were found for apolipoprotein A I, apolipoprotein B, and high density lipoprotein-cholesterol. Children of parents with CHD differed from controls in total cholesterol and apolipoprotein A II concentrations. A highly significant difference furthermore was found in lipoprotein (a) concentrations from children of parents with CHD in comparison with controls, but not between children of parents with CVD and controls. The difference in lipoprotein (a) concentrations (children of parents with CHD compared with controls) were only noticed in children above the age of 10 years. This could be explained by the observed rise of lipoprotein (a) between age 2 and 13 years, which was much more pronounced in the group with parents who had CHD. Plasma glycosaminoglycan concentrations were also measured in the three groups. They were significantly higher in children of parents with CHD and CVD compared with controls; they also varied with age.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929512      PMCID: PMC1793056          DOI: 10.1136/adc.66.9.1054

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

2.  Apolipoproteins AI, AII and HDL phospholipids but not APO-B are risk indicators for occlusive cerebrovascular disease.

Authors:  G M Kostner; E Marth; K P Pfeiffer; H Wege
Journal:  Eur Neurol       Date:  1986       Impact factor: 1.710

3.  Lipoprotein Lp(a). A risk factor for myocardial infarction.

Authors:  G Hoefler; F Harnoncourt; E Paschke; W Mirtl; K H Pfeiffer; G M Kostner
Journal:  Arteriosclerosis       Date:  1988 Jul-Aug

4.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.

Authors:  A Murai; T Miyahara; N Fujimoto; M Matsuda; M Kameyama
Journal:  Atherosclerosis       Date:  1986-02       Impact factor: 5.162

5.  Lipoprotein Lp(a) and the risk for myocardial infarction.

Authors:  G M Kostner; P Avogaro; G Cazzolato; E Marth; G Bittolo-Bon; G B Qunici
Journal:  Atherosclerosis       Date:  1981 Jan-Feb       Impact factor: 5.162

6.  Relationship between 'sinking pre-beta-lipoprotein' (Lp(a) lipoprotein) and age in a family kindred.

Authors:  A Pagnan; G Kostner; M Braggion; L Ziron
Journal:  Gerontology       Date:  1982 Nov-Dec       Impact factor: 5.140

7.  Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males.

Authors:  K Berg; G Dahlén; A L Børresen
Journal:  Clin Genet       Date:  1979-11       Impact factor: 4.438

8.  Serum apolipoproteins and lipoprotein (a) during the first week of life.

Authors:  W Strobl; K Widhalm; G Kostner; A Pollak
Journal:  Acta Paediatr Scand       Date:  1983-07

9.  Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta.

Authors:  M Bihari-Varga; E Gruber; M Rotheneder; R Zechner; G M Kostner
Journal:  Arteriosclerosis       Date:  1988 Nov-Dec

10.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Authors:  V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162

  10 in total
  5 in total

Review 1.  Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.

Authors:  Wann Jia Loh; Dick C Chan; Pedro Mata; Gerald F Watts
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

Review 2.  Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions.

Authors:  Ozlem Bilen; Ayeesha Kamal; Salim S Virani
Journal:  World J Cardiol       Date:  2016-03-26

3.  Lipoprotein(a) and cardiovascular risk factors in a cohort of 6-year-old children. The Rivas-Vaciamadrid Study.

Authors:  Angel Gonzalez-Requejo; Marciano Sanchez-Bayle; Consuelo Ruiz-Jarabo; Juliana Asensio-Anton; Maria Jesus Pelaez; Maria Teresa Morales; Epifania Anton-Pacheco; Margarita Fernandez-Calle; Elsa Madera-Cruz
Journal:  Eur J Pediatr       Date:  2003-06-19       Impact factor: 3.183

4.  Lipoprotein (a) in childhood: correlations with family history of cardiovascular disease.

Authors:  M De Simone; A Verrotti; M Cappa; L Iughetti; E Di Cesare; M Palumbo; R Bernabei; T Rosato
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

5.  The role of exercise training on lipoprotein profiles in adolescent males.

Authors:  Majid S Koozehchian; Farzad Nazem; Richard B Kreider; William J Roberts; Thomas M Best; Yi Rong; Li Zuo
Journal:  Lipids Health Dis       Date:  2014-06-09       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.